Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study

Psychopharmacology

Volumn 166, Issue 4, 2003, Pages 391-399

  Casey, Daniel E ^a   Carson, William H ^b   Saha, Anutosh R ^b   Liebeskind, Amy ^c   Ali, Mirza W ^b   Jody, Darlene ^d   Ingenito, Gary G ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c LENOX HILL HOSPITAL   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic; Schizophrenia; Switching

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE; THIORIDAZINE;

ADULT; AGITATION; AKATHISIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NAUSEA; PARKINSONISM; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; WEIGHT REDUCTION;

EID: 0037393107     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1344-3     Document Type: Article

References (39)

1. Barnes TRE (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676
2. Bunney WE, Meltzer HY (1995) Schizophrenia - overview. Clin Neurosci 3:55-56
3. 2 dopamine receptors. Int J Psychopharmacol 3:S129
4. Carson WH, McQuade RD, Ali M, Saha AR, Dunbar GC, Ingenito GA (2001) A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophrenia Res (Special Issue VIIIth International Congress on Schizophrenia Research, Whistler, British Columbia, Canada) 49:221
5. Carson WH, Stock E, Saha AR, Ali M, McQuade RD, Kujawa MJ, Ingenito G (2002) Meta-analysis of safety and tolerability with aripiprazole. Abstracts of the XIth Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February 24-March 1 2002. Schizophr Res 53:1-274
6. Casey DE (1997) The relationship of pharmacology to side effects. J Clin Psychiatry 58:55-62
7. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6:70-87
8. Dossenbach MRK, Beuzen JN, Avnon M, Belmaker RH, Elizur A, Mark M, Munitz H, Schneidman M, Shoshani D, Kratky P, Grundy SL, Tollefson GD (2000) The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther 22:1021-1034
9. Dossenbach MR, Kratky P, Schneidman M, Grundy SL, Metcalfe S, Tollefson GD, Belmaker RH (2001) Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 6:28-34
10. Fleischhacker WW, Meise U, Gunther V, Kurz M (1994) Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand Suppl 382:11-15
11. Glennon RA, Dukat M (1995) Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology. The fourth generation of progress. Raven Press, New York, pp 415-430
12. Goodnick PJ, Kato MM (2001) Antipsychotic medication: effects on regulation of glucose and lipids. Exp Opin Pharmacother 2:1571-1582
13. Guy W (1976a) Abnormal involuntary movement scale (AIMS). National Institute of Mental Health. In: ECDEU Assessment Manual for Psychopharmacology, Revised 1976. National Institute of Mental Health, Psychopharmacology Research Branch, Division of Basic Brain and Behavioral Sciences, Rockville, Md.
14. Guy W (1976b) Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Rockville, Md., pp. 218-222
15. Inoue T, Domae M, Yamada K, Furukawa T (1996) Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)- quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277:137-143
16. Jan MW (1988) Buspirone: an update on a unique anxiolytic agent. Pharmacotherapy 8:100-116
17. 1A receptor. Eur Neuropsychopharmacol 11:S268
18. Kane JM (1987) Treatment of schizophrenia. Schizophr Bull 13:133-156
19. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771
20. Kay SR, Opler LA, Fiszbein A (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276
21. 2 receptor antagonist activity. J Pharmacol Exp Ther 274:329-336
22. Kinon BJ, Kane JM, Johns C et al. (1993) Treatment of neuroleptic resistant schizophrenia relapse. Psychopharmacol Bull 29:309-314
23. Kinon BJ, Basson BR, Gilmore, JA, Malcolm S, Stauffer VL (2000) Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 61:833-840
24. Kolakowska T, Williams AO, Arden M et al. (1985) Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146:229-239
25. Kurzthaler I, Fleishhacker WW (2001) The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 62:32-37
26. 2 receptors. Psychopharmacology 112:S40
27. Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz BL and Howard A (1988) Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 49:271-277
28. Littrell KH, Johnson CG, Hilligoss NM, Peabody CD, Littrell SH (2000) Switching clozapine responders to olanzapine. J Clin Psychiatry 61:912-915
29. McIntyre RS, Mancini DA, Basile VS (2001) Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 62:23-29
30. Meltzer HY (2001) Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry 62:35-39
31. Meyer JM (2001) Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 62:27-34
32. 1A receptors. J Pharmacol Exp Ther 295:853-861
33. Peuskens J (2000) Switching approach in the management of schizophrenia patients. Int Clin Psychopharmacol 15:S15-19
34. Remington G, Chong S-A (1999) Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatr Neurosci 24:431-441
35. Saha AR, Carson WH, Ali MW, Dunbar GC, Ingenito G (2001) Efficacy and safety of aripiprazole and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. W J Biol Psychiatry 2:305S
36. Simpson GM, Angus JSW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 45:11-19
37. Sovner R, Pamer-Sovner N (1989) Use of buspirone in the treatment of schizophrenia. J Clin Psychopharmacol 9:61-61
38. Sussman N (2001) Review of atypical antipsychotics and weight gain. J Clin Psychiatry 62:5-12
39. Yeung PP, Carson WH, Saha AR, McQuade RD, Ali MW, Stringfellow JC, Ingenito G (2001) Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo-controlled trial with risperidone. Eur Neuropsychopharmacol 11:S241